Alert

Labcorp Inc. (LH)

NYSE: LH · Real-Time Price · USD

323.48

+1.06 (0.33%)

At close: Aug 12, 2026, 3:59 PM

0.33% (1D)

Bid	315.33
Market Cap	26.23B
Revenue (ttm)	14.35B
Net Income (ttm)	1B
Beta	0.84
EPS (ttm)	12.09
PE Ratio (ttm)	26.67
Forward PE	16.35
P/B (ttm)	3.04
P/S (ttm)	1.83
Earnings Date	Nov 3, 2026

Ask	326
Volume	291,991
Avg. Volume (20D)	667,135
Open	316.13
Previous Close	322.42
Day's Range	315.33 - 323.63
52-Week Range	244.52 - 323.97
Analyst	Buy
Price Target	350 (8.20%)
Dividends	$2.88 (0.89%)
Ex-Dividend Date	Aug 28, 2026

About LH

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialt...

[Read more]

Industry Diagnostics & Research

Sector Healthcare

IPO Date Mar 29, 1990

Employees 71,000

Stock Exchange NYSE

Ticker Symbol LH

Website https://www.labcorp.com

Full Company Profile

Financial Performance

In 2025, Labcorp's revenue was 13.95B, an increase of 7.25% compared to the previous year's 13.01B. Earnings were 876.5M, an increase of 17.49%.

Financial Statements

Analyst Forecast

According to 16 analyst ratings, the average rating for LH stock is "Buy". The 12-month stock price forecast is 350, which is upside of 8.2% from the latest price.

Stock Forecasts

Earnings Surprise

Labcorp has released their quarterly earnings on Jul 30, 2026:

Revenue of $3.73B misses estimates by $0, with 5.78% YoY growth.

EPS of 4.99 exceeds estimates by 0.22, with 14.71% YoY growth.

Next Earnings Release

Labcorp Inc. is scheduled to release its earnings on Nov 3, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

2 hours ago · Motley Fool

Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million

Schechter maintains a $33 million stake after this pre-scheduled sale under a Rule 10b5-1 plan.

6 hours ago · Simply Wall St.

Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?

Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENT...

18 hours ago · Simply Wall St.

Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?

In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded ...